Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Biliary Tract Diseases

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 21 articles:
HTML format



Single Articles


    June 2025
  1. NAITOH I, Isayama H, Akamatsu N, Mizuno S, et al
    The 2024 diagnostic criteria for primary sclerosing cholangitis.
    J Gastroenterol. 2025 Jun 12. doi: 10.1007/s00535-025-02265.
    PubMed     Abstract available


    May 2025
  2. ZHU J, Chen H, Meng L, Jiang J, et al
    Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia.
    J Gastroenterol. 2025 May 5. doi: 10.1007/s00535-025-02234.
    PubMed     Abstract available


    April 2025
  3. YOSHIDA M, Toyohara T, Hori Y, Kato A, et al
    Endoscopic liquid biopsy of bile: superior diagnostic and prognostic performance of bile-derived exosomal miR-21-5p for biliary tract cancers.
    J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02250.
    PubMed     Abstract available


    February 2025
  4. HAO Z, Lu Y, Hao Y, Luo Y, et al
    Correction: Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis.
    J Gastroenterol. 2025 Feb 27. doi: 10.1007/s00535-025-02217.
    PubMed    


  5. TANAKA A, Notohara K, Tobari M, Abe M, et al
    A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
    J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
    PubMed     Abstract available


    November 2024
  6. HAO Z, Lu Y, Hao Y, Luo Y, et al
    Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis.
    J Gastroenterol. 2024 Nov 27. doi: 10.1007/s00535-024-02183.
    PubMed     Abstract available


  7. YASUDA M, Shiokawa M, Kuwada T, Nishikawa Y, et al
    Anti-integrin alphavbeta6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
    J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169.
    PubMed     Abstract available


  8. CAO Z, Yang Y, Liu S, Sun L, et al
    FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
    PubMed     Abstract available


    August 2024
  9. TAKAOKA S, Hamada T, Nakai Y, Yasunaga H, et al
    Response to the letter by Buldukoglu et al. regarding our manuscript "Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation".
    J Gastroenterol. 2024 Aug 6. doi: 10.1007/s00535-024-02143.
    PubMed    


    July 2024
  10. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    PubMed     Abstract available


    June 2024
  11. TAKAOKA S, Hamada T, Takahara N, Fukuda R, et al
    Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation.
    J Gastroenterol. 2024 Jun 19. doi: 10.1007/s00535-024-02124.
    PubMed     Abstract available


    May 2024
  12. KANO Y, Ishikawa T, Yamao K, Mizutani Y, et al
    What is the appropriate method of pathological specimen collection for cholangiocarcinoma detection in primary sclerosing cholangitis?
    J Gastroenterol. 2024 May 7. doi: 10.1007/s00535-024-02105.
    PubMed     Abstract available


    March 2024
  13. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    PubMed     Abstract available


    October 2023
  14. WU JF, Peng SS, Tai CS, Lin WH, et al
    The magnetic resonance imaging and age-adjusted matrix metalloproteinase-7 assist the diagnosis of biliary atresia.
    J Gastroenterol. 2023 Oct 30. doi: 10.1007/s00535-023-02051.
    PubMed     Abstract available


  15. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    PubMed     Abstract available


    September 2023
  16. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    PubMed     Abstract available


    July 2023
  17. FUJITA N, Yasuda I, Endo I, Isayama H, et al
    Evidence-based clinical practice guidelines for cholelithiasis 2021.
    J Gastroenterol. 2023 Jul 15. doi: 10.1007/s00535-023-02014.
    PubMed     Abstract available


  18. PENG M, Li H, Cao H, Huang Y, et al
    Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2023 Jul 11. doi: 10.1007/s00535-023-02012.
    PubMed     Abstract available


    June 2023
  19. XU H, Lin X, Li Z, He X, et al
    VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
    J Gastroenterol. 2023 Jun 30. doi: 10.1007/s00535-023-02015.
    PubMed     Abstract available


  20. YOSHIDA H, Shiokawa M, Kuwada T, Muramoto Y, et al
    Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis.
    J Gastroenterol. 2023 Jun 13. doi: 10.1007/s00535-023-02006.
    PubMed     Abstract available


    May 2023
  21. KIM KA, Choi HY, Ki M, Jang ES, et al
    Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
    J Gastroenterol. 2023 May 17. doi: 10.1007/s00535-023-01999.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.